Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anumigilimab in HS and PPP
NCT03972280Phase 1Completed
- Sponsor
- CSL Limited
- Start
- Jul 2019
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of anumigilimab in hidradenitis suppurativa (HS) and palmoplantar pustulosis (PPP) (4 arms), sponsored by CSL Limited. Primary endpoints: Treatment-Emergent Adverse Events at 24 weeks, Adverse Events of Special Interest: Grade 3 and 4 Neutropenia at 24 weeks and 1 more. Started Jul 2019; status: completed.
02
Drugs
anumigilimab
03
Conditions
hidradenitis suppurativa (HS)palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT03972280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03972280.